Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 56

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 56
---
 the completion of the Transactions. In addition, neither Clearwater nor Enfusion can provide assurance that any such conditions, terms, obligations or restrictions will not result in the delay or abandonment of the Transactions. See the sections titled “The Transactions—Regulatory Clearances and Approvals” and “The Merger Agreement—Conditions to the Transactions.” Enfusion’s directors and executive officers have interests in the Transactions that may be different from, or in addition to, your interests as a stockholder of Enfusion more generally. When considering the recommendation of the Enfusion Board that Enfusion Stockholders vote in favor of the Merger Agreement Proposal and the Adjournment Proposal, Enfusion Stockholders should be aware of the fact that, aside from their interests as Enfusion Stockholders, certain Enfusion directors and executive officers have interests in the Transactions that may be different from, or in addition to, the interests of Enfusion Stockholders generally. These interests include:

| • |     | rights to continuing indemnification and directors’ and officers’ liability insurance; |

| • |     | certain executive officers and other employees of Enfusion may receive cash transaction and transition bonuses in 
 connection with the Transactions;                                                                                 |

| • |     | at the Effective Time, each Enfusion Equity Award (as defined below) held by an executive officer will receive                             
 the treatment described in the section titled “The Merger Agreement—Treatment of Enfusion Equity Awards and Employee Stock Purchase Plan”; |

| • |     | at the Effective Time, each Enfusion RSU held by an Enfusion non-employee                             
 director will accelerate and vest pursuant to the Enfusion non-employee director compensation policy; |

| • |     | in the event an executive officer’s employment with Enfusion is involuntarily terminated in connection with                                                                                                                  
 or following the Transactions, vesting of certain Enfusion RSUs, including Enfusion PSUs converted into Enfusion RSUs (or corresponding Assumed RSUs) may be accelerated in accordance with the terms of such Enfusion RSUs; |

| • |     | eligibility of Enfusion’s executive officers to receive severance payments and benefits either under their        
 employment agreement with Enfusion or under the Enfusion Executive Severance Policy (the “Severance Policy”); and |

| • |     | with respect to Enfusion officers and directors who may be, or may be affiliated with, the TRA Parties, rights to 
 receive portions of the $30 million early termination payment under the TRA.                                      |

33

See